GRAIL (GRAL) Tariff Resilience Score: 7/10 (As of Jun. 30, 2026)


GRAL GRAIL Inc GRAL
12 GF Score
Price $67.93
! 2 Warning Signs
View Full Analysis

What is GRAIL Tariff Resilience Score?

GRAIL GRAL -0.68% 12 Tariff Resilience Score is 7 as of Jun. 30, 2026. GuruFocus rates GRAL with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, GRAIL ranks better than 95.81% on this metric.

GRAIL has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

GRAIL has GRAIL Inc, a healthcare company, has moderate tariff exposure. While it relies on imported medical equipment, the healthcare sector often benefits from tariff exemptions. The company can mitigate risks through alternative suppliers and has some pricing power due to its innovative product offerings.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes GRAIL might have Highly Resilient.

GRAIL  (NAS:GRAL) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

GRAIL Tariff Resilience Score Related Terms

GRAL vs ADPT, WGS, NEO: Tariff Resilience Score Comparison

For the Diagnostics & Research subindustry, GRAIL's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GRAIL Tariff Resilience Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, GRAIL's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where GRAIL's Tariff Resilience Score falls into.


GRAL
12GF Score
GRAIL Inc GRAL
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
GRAIL (GRAL) has a Tariff Resilience Score of 7 as of Jun. 30, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, GRAIL ranks #9 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 4.2%.
Is GRAIL's Tariff Resilience Score too high?
GRAIL's current Tariff Resilience Score is 7. Based on the distribution chart, GRAIL ranks #9 out of 215 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, GRAIL has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does GRAIL's Tariff Resilience Score compare to ADPT and WGS?
According to the Medical Diagnostics & Research industry distribution chart, GRAIL ranks #9 out of 215 companies for Tariff Resilience Score. This places GRAIL in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Diagnostics & Research company?
A good Tariff Resilience Score depends on the Medical Diagnostics & Research industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. GRAIL's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GRAIL stock overvalued right now?
GRAIL (GRAL) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7. GRAIL's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For GRAIL (GRAL), the current Tariff Resilience Score is 7 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GRAIL Business Description

Other Exchanges NL0:Germany
Address 1525 O’Brien Drive, Menlo Park, CA, USA, 94025
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
12GF Score

Get the complete analysis for GRAL

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$67.93
Price